A week after Britain’s debut of the four-week Kwikpen, a European Medicines Agency panel is slated to review Eli Lilly’s multi-dose, pre-filled pen injector for diabetes drug Mounjaro.
Tag Archive for: obesity drugs
It was last year’s hottest topic, and this year it is sure to be at the top of the list. It dominates conversations, and it sure does dominate my inbox. Artificial intelligence.
Even as they are gathering proof of extensive benefits to patients, the manufacturers of GLP-1s will have to overcome supply chain difficulties and high prices to get payers to fund these medicines for treating obesity.
Med Ad News chats with Ellen Cappellino, executive director of value, access & reimbursement strategy at Klick Health about the obesity drug market and payer attitudes towards the GLP-1s.
Eli Lilly’s Mounjaro is being launched in Britain this week, two pharmacy companies said on Wednesday, making the UK the fourth European country to introduce the highly anticipated obesity drug.
“We are very pleased with the agreement to acquire the three Catalent manufacturing sites which will enable us to serve significantly more people living with diabetes and obesity in the future,“ said Lars Fruergaard Jørgensen, president and chief executive officer at Novo Nordisk.
The strategic acquisition provides Roche access to Carmot’s portfolio, which notably includes three lead molecules, all GLP-1 analogues, currently in the advanced stages of clinical trials for obesity and type 2 diabetes. It also positions the company on par with other industry leaders in the realm of GLP-1 analogues, such as Novo Nordisk, Eli Lilly and others.
Pharmaceutical executives from Amgen to Pfizer are plotting to break into the lucrative obesity market by developing or cutting deals to acquire better drugs that will compete with Novo Nordisk’s Wegovy and Zepbound from Eli Lilly .
Some of the biggest trends in pharma will also be affecting the medtech industry next year.
Kidney dialysis kit-makers look set to be the latest victim of the obesity drug boom. On Wednesday, shares in Germany-listed Fresenius Medical Care fell 20% after a medical trial showed a Novo Nordisk drug can reduce the risk of kidney failure.
